Physicians and partners proved harder to impress than casual chatbot users, and 2026's biggest AI valuations rewarded the startups that impressed them anyway. Abridge, the medical-scribe company Shiv Rao founded, doubled to a $5.3 billion valuation in four months during 2025 1. OpenEvidence, built by Kensho Technologies founder Daniel Nadler, doubled again, from $6 billion to $12 billion, inside roughly twelve weeks 23. Harvey and Legora, the two legal-AI companies now locked in open competition, each crossed multibillion-dollar marks of their own, backed in Harvey's case by Goldman Sachs and J.P. Morgan directly 456.
Medicine's Documentation Boom
Rao's Abridge sells an AI scribe that listens to clinical encounters and drafts documentation, a category that sounds narrow until the valuation curve reveals otherwise. TechCrunch reported the company's valuation doubling to $5.3 billion within four months during June 2025, one of the fastest re-pricings any health-tech startup had posted 1. Momentum carried into 2026: Abridge hired San Oo as chief technology officer in May, and Forbes named Rao to its inaugural list of "America's 250 Greatest Living Innovators" that February 1.
Clinical documentation occupies hours physicians would rather spend with patients, a pain point specific enough that a general-purpose assistant struggles to match a tool built around medical terminology, billing codes, and malpractice-conscious phrasing. Abridge's bet holds that specificity beats breadth inside a workflow this regulated.
The ChatGPT for Doctors Doubles Down
Nadler positioned OpenEvidence as "the ChatGPT for doctors," a product built for point-of-care clinical questions rather than general conversation, and his prior exit gave the pitch unusual credibility 2. Kensho Technologies, the company Nadler founded before OpenEvidence, sold in a deal OpenEvidence's own materials describe as the most valuable AI acquisition recorded up to that point, a pedigree investors weighed heavily when pricing the new venture 2.
TechCrunch's Rebecca Bellan reported a $200 million round at a $6 billion valuation in October 2025 2; three months later, Julie Bort reported Thrive Capital and DST Global leading a fresh round that pushed valuation to $12 billion 3. Two funding events, twelve weeks apart, doubling the company's worth each time, tell a story about physician trust translating directly into venture pricing once a product proves it saves clinical time while preserving accuracy.
Law's Two-Horse Race Becomes Three-Way Pressure
Harvey built its reputation selling agentic legal research and drafting tools into the largest firms in the world, and 2026 brought both capital and credibility validation. The company's own newsroom confirmed an $11 billion valuation round in March, framed explicitly around scaling agents across law firms and enterprises 4. Goldman Sachs and J.P. Morgan followed with a strategic investment in July, an unusual move for two banks that typically finance legal-tech vendors rather than take equity stakes in them 4. Harvey closed the summer by earning AIUC-1 certification, described on its own site as the first certified AI agents in the legal category, and by hiring Steve Zad as chief revenue officer in early August 4. Adoption numbers back the funding: Harvey counts more than 2,400 law firms and in-house legal teams, over 200,000 individual professionals, upward of 75 AmLaw 100 firms, and users across 70-plus countries 4.
Legora, the Swedish challenger founded by Max Junestrand, refused to cede ground. TechCrunch's Anna Heim reported a $5.55 billion valuation in March 2026, then a $5.6 billion figure by April, coverage that explicitly framed the round as intensifying Legora's rivalry with Harvey 56. A marketing campaign featuring actor Jude Law accompanied the April announcement, an unusual celebrity play for enterprise legal software and evidence Legora intends to compete on brand recognition alongside product capability 6. Sweden's broader startup ecosystem gained recognition alongside Legora too, with coverage grouping the company beside Lovable as evidence of the country's outsized AI output 6.
Capital Chases Clinical and Courtroom Credibility
Health care and law share a structural feature that explains why both fields produced 2026's biggest vertical AI valuations: both sell to professionals whose liability exposure makes them unusually cautious buyers, and both reward a vendor that earns trust once with years of expanding usage afterward. Ambience Healthcare, backed early by OpenAI and Kleiner Perkins in a 2024 round, staked out similar territory to Abridge, evidence the clinical-documentation category drew multiple well-capitalized entrants rather than consolidating around a single winner immediately.
Investors chasing these categories accept a tradeoff general-purpose AI companies rarely face: a narrower addressable market in exchange for defensibility built from domain expertise, compliance infrastructure, and the kind of professional word-of-mouth that outpaces any advertising budget. Rao's medical background and Nadler's Kensho pedigree gave both founders credibility with skeptical buyers before either company shipped a product, a head start general AI labs entering health care or law from the outside rarely carry. Junestrand's Legora and Rao's Abridge alike leaned on founder-market fit as a recruiting pitch, too, using domain credibility to hire clinicians and lawyers willing to trade billable-hour income for equity in a category they understood from the inside.
What Verticals Prove About Horizontal Models
Read together, Abridge, OpenEvidence, Harvey, and Legora argue against a winner-take-all future for foundation models alone. General-purpose chatbots handle breadth well, yet a cardiologist documenting a complex visit or a litigator drafting a motion under deadline pressure needs a tool tuned to that exact workflow, trained on that exact vocabulary, and backed by a vendor willing to accept liability questions a horizontal platform would rather avoid. Capital increasingly follows that logic, rewarding founders who chose depth over reach.
By the numbers
- Abridge's valuation reached $5.3 billion after doubling in four months, reported June 2025 1.
- OpenEvidence's valuation hit $6 billion following its October 2025 raise 2.
- Twelve weeks later, OpenEvidence reached $12 billion in valuation, January 2026 3.
- Harvey's valuation climbed to $11 billion following its March 2026 funding round 4.
- More than 2,400 law firms and in-house legal teams use Harvey, per the company's own figures 4.
- Legora's valuation reached $5.6 billion by April 2026, up from $5.55 billion the prior month 56.
What to watch
Harvey's Goldman Sachs and J.P. Morgan investment deserves a follow-up look for signs of deeper banking-sector integration, given how rarely large banks take direct equity positions in legal-tech vendors. OpenEvidence's next funding milestone will show whether the twelve-week doubling pace from late 2025 into 2026 continues or settles into a steadier trajectory more typical of health-tech growth. Legora's Jude Law campaign offers a natural test of whether celebrity marketing moves enterprise software buying decisions the way it moves consumer ones, worth tracking through the next funding cycle. Abridge's CTO hire under San Oo bears watching for product roadmap signals, particularly around expansion beyond documentation into broader clinical decision support.
Sources
- Marina Temkin, "In Just 4 Months, AI Medical Scribe Abridge Doubles Valuation to $5.3B," TechCrunch, June 24, 2025, https://techcrunch.com/tag/abridge/
- Rebecca Bellan, "OpenEvidence, the ChatGPT for Doctors, Raises $200M at $6B Valuation," TechCrunch, Oct. 20, 2025, https://techcrunch.com/tag/openevidence/
- Julie Bort, "OpenEvidence Hits $12B Valuation, With New Round Led by Thrive, DST," TechCrunch, Jan. 21, 2026, https://techcrunch.com/tag/openevidence/
- Harvey, "Harvey Newsroom," Harvey, Aug. 4, 2026, https://www.harvey.ai/en-US/newsroom
- Anna Heim, "Legora Reaches $5.55 Billion Valuation as AI Legal Tech Boom Endures," TechCrunch, March 10, 2026, https://techcrunch.com/tag/legora/
- Anna Heim, "Legal AI Startup Legora Hits $5.6B Valuation and Its Battle With Harvey Just Got Hotter," TechCrunch, April 30, 2026, https://techcrunch.com/tag/legora/